- We will send in 10–14 business days.
/images/books/5809710/9781138898424.jpg)
- Author: Reji K Joseph
- Publisher: Routledge Chapman & Hall
- ISBN-10: 1138898422
- ISBN-13: 9781138898424
- Format: 13.7 x 21.8 x 1.8 cm, hardcover
- Language: English
- SAVE -10% with code: EXTRA
Pharmaceutical Industry and Public Policy in Post-Reform India (e-book) (used book) | bookbook.eu
Reviews
Description
This book examines the impact of economic reforms in India on the pharmaceutical industry and access to medicines. It traces the changing production and trade pattern of the industry, research and development (R&D) preferences and strategies of Indian pharmaceutical firms, patent system alongside pricing policy measures and their shortcomings. It also analyses the public health financing system in India driven largely by out-of-pocket expenditure -- about 60 per cent -- and characterised by very high share of medicines in total health expenditure.
A masterful insight into a topical area, the work will be indispensable to those working on pharmaceutical industry and public policy. It will be of interest to researchers, scholars, students, and policy-makers of economics, industrial policy, public policy, intellectual property rights and health financing.
EXTRA 10 % discount with code: EXTRA
The promotion ends in 16d.22:12:42
The discount code is valid when purchasing from 10 €. Discounts do not stack.
- Author: Reji K Joseph
- Publisher: Routledge Chapman & Hall
- ISBN-10: 1138898422
- ISBN-13: 9781138898424
- Format: 13.7 x 21.8 x 1.8 cm, hardcover
- Language: English English
This book examines the impact of economic reforms in India on the pharmaceutical industry and access to medicines. It traces the changing production and trade pattern of the industry, research and development (R&D) preferences and strategies of Indian pharmaceutical firms, patent system alongside pricing policy measures and their shortcomings. It also analyses the public health financing system in India driven largely by out-of-pocket expenditure -- about 60 per cent -- and characterised by very high share of medicines in total health expenditure.
A masterful insight into a topical area, the work will be indispensable to those working on pharmaceutical industry and public policy. It will be of interest to researchers, scholars, students, and policy-makers of economics, industrial policy, public policy, intellectual property rights and health financing.
Reviews